PTC Therapeutics, Inc. (NASDAQ:PTCT) VP Mark Elliott Boulding sold 15,312 shares of the business’s stock in a transaction dated Friday, July 5th. The stock was sold at an average price of $44.74, for a total transaction of $685,058.88. Following the completion of the sale, the vice president now directly owns 32,805 shares of the company’s stock, valued at approximately $1,467,695.70. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Mark Elliott Boulding also recently made the following trade(s):

  • On Friday, June 28th, Mark Elliott Boulding sold 77,575 shares of PTC Therapeutics stock. The stock was sold at an average price of $45.00, for a total transaction of $3,490,875.00.
  • On Monday, July 1st, Mark Elliott Boulding sold 181,667 shares of PTC Therapeutics stock. The stock was sold at an average price of $45.00, for a total transaction of $8,175,015.00.

PTCT opened at $43.46 on Friday. The business has a 50-day moving average of $42.06. The company has a market cap of $2.58 billion, a P/E ratio of -23.62 and a beta of 1.76. PTC Therapeutics, Inc. has a 1-year low of $27.53 and a 1-year high of $48.99. The company has a debt-to-equity ratio of 0.27, a current ratio of 3.35 and a quick ratio of 3.24.

PTC Therapeutics (NASDAQ:PTCT) last posted its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($1.29) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.74) by ($0.55). PTC Therapeutics had a negative net margin of 68.99% and a negative return on equity of 32.42%. The business had revenue of $53.58 million during the quarter, compared to analyst estimates of $70.38 million. During the same period last year, the firm posted ($0.46) earnings per share. The company’s quarterly revenue was down 4.4% on a year-over-year basis. As a group, sell-side analysts expect that PTC Therapeutics, Inc. will post -2.54 earnings per share for the current year.

Hedge funds and other institutional investors have recently bought and sold shares of the company. BlackRock Inc. raised its stake in shares of PTC Therapeutics by 1.9% in the 4th quarter. BlackRock Inc. now owns 3,707,241 shares of the biopharmaceutical company’s stock valued at $127,233,000 after acquiring an additional 67,532 shares during the period. Bank of New York Mellon Corp raised its stake in shares of PTC Therapeutics by 33.7% in the 4th quarter. Bank of New York Mellon Corp now owns 258,004 shares of the biopharmaceutical company’s stock valued at $8,854,000 after acquiring an additional 65,061 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of PTC Therapeutics by 15.7% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 37,036 shares of the biopharmaceutical company’s stock valued at $1,271,000 after acquiring an additional 5,036 shares during the period. Raymond James & Associates purchased a new position in shares of PTC Therapeutics in the 4th quarter valued at $253,000. Finally, NumerixS Investment Technologies Inc purchased a new position in shares of PTC Therapeutics in the 4th quarter valued at $32,000.

PTCT has been the subject of several research analyst reports. Cowen reissued a “buy” rating and issued a $149.00 target price on shares of Intercept Pharmaceuticals in a research report on Wednesday, May 8th. Citigroup set a $47.00 target price on shares of Quanta Services and gave the stock a “buy” rating in a research report on Friday, May 3rd. Zacks Investment Research downgraded shares of GENEL ENERGY PL/ADR from a “hold” rating to a “sell” rating in a research report on Thursday, July 4th. Sanford C. Bernstein set a €12.10 ($14.07) target price on shares of Metro and gave the stock a “sell” rating in a research report on Thursday, April 11th. Finally, ValuEngine raised shares of United Overseas Bank from a “sell” rating to a “hold” rating in a research report on Monday, June 17th. Three analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $50.56.

PTC Therapeutics Company Profile

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for the treatment of rare disorders. The company offers Translarna (ataluren) and Emflaza (deflazacort) for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients.

Featured Article: What is the Fibonacci sequence?

Insider Buying and Selling by Quarter for PTC Therapeutics (NASDAQ:PTCT)

Receive News & Ratings for PTC Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PTC Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.